US4609640A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preparation having excellent absorption property
Assignee: Toyo Jozo KK
•
Filing: 1982-01-25
•
Granted: 1986-09-02
•
Expires: 2002-01-25
Abstract
Abstract A preparation containing an absorption promoter selected from specific classes of water-soluble macromolecular compounds having chelating activity, preferably in the presence of a salt at a concentration such that the composition exhibits higher osmotic pressure than isotonic sodium chloride solution, and a medicine is found to promote absorption of the medicine through a gastrointestinal organ such as the colon, rectum, or vagina.
Inventors
- 👤 Masataka Morishita
- 👤 Renji Aikawa
- 👤 Yoshiaki Yamamoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 17:59
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/30; A61K47/42; A61K47/02; A61K47/06; A61K47/08; A61K47/12; A61K47/14; A61K47/16; A61K47/18; A61K47/183; A61K47/20; A61K47/24; A61K47/26; A61K47/32; A61K47/36; A61K47/38; A61K9/00; A61K9/0012; A61K9/0031; A61K9/0034; B; B01; B01F; B01F25/00; B01F25/80
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
108 words
A therapeutic composition for rectal or vaginal administration having excellent absorption properties and containing a therapeutically effective amount of a water soluble therapeutic agent having a partition coefficient of up to 50 in chloroform/water, and additionally containing from 0.1 to 50 w/w% of a water soluble chelating agent selected from the group consisting of polysaccharide compounds, cellulose compounds, starch compounds, dextrose compounds, polypeptides and synthetic polymers, said agent being capable of chelating calcium or magnesium ions, having a molecular weight of from 1000 to 1,000,000, and containing at least two chelating ligands selected from the group consisting of carboxylic, sulfonic, phosphoric, phenolic, hydroxyl, carbonyl, imino and amino groups.
Claim 2
Dependent Claim
108 words
A therapeutic composition for rectal or vaginal administration having excellent absorption properties and containing a therapeutically effective amount of a water soluble therapeutic agent having a partition coefficient of up to 50 in chloroform/water, and additionally containing from 0.1 to 50 w/w% of a water soluble chelating agent selected from the group consisting of polysaccharide compounds, cellulose compounds, starch compounds, dextrose compounds, polypeptides and synthetic polymers, said agent being capable of chelating calcium or magnesium ions, having a molecular weight of from 1000 to 1,000,000, and containing at least two chelating ligands selected from the group consisting of carboxylic, sulfonic, phosphoric, phenolic, hydroxyl, carbonyl, imino and amino groups.
Claim 3
Dependent Claim
70 words
A therapeutic composition of claim 1 wherein the chelating agent is selected from the group consisting alginic acid, pectinic acid chondroitin sulfate hyaluronic acid, arabic acid; carboxymethyl cellulose, carboxyethyl cellulose, carboxypropyl cellulose, cellulose acetate phthalate; carboxymethyl starch, carboxyethyl starch; carboxymethyl dextran, dextran sulfate; polyglutamic acid, poly-γ-carboxyglutamic acid, polyaspartic acid, polylysine, polyalginine and copolymers of these amino acids; polyacrylic acid, polymethacrylic acid, methacrylic acid-acrylic acid copolymer, acrylamide-acrylic acid copolymer polyphosphoric acid.
Claim 4
Dependent Claim
98 words
A therapeutic composition of claim 1 wherein the chelating agent is selected from the group consisting chondroitin sulfate heparin, arabic acid, pectin, gum tragacanth, tragacanthic acid, pectinic acid; carrageenan, -glucan galactomammam, konjakmannan, galactan, fucan, inulin, levan; hydroxyethyl cellulose, hydroxypropyl cellulose, cellulose, methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, agarose; soluble starch phosphoric acid starch, cetyl starch, hydroxyethyl starch, dextrin, anylose, amylopectin; dextran, diethylaminoethyl dextran, aminoethyl dextran; gelatin, casein, albumin, globulin; polyethylene glycol, polyvinyl alcohol, polyethylene oxide, vinyl acetate-maleic acid copolymer, vinyl acetate-crotonic acid copolymer, vinyl acetate-acrylic acid copolymer, polyvinyl alcohol-maleic acid copolymer, polyacrylamide, polyvinylacetal diethylaminoacetate, 2-methyl-5-vinylpyridine/methyl acrylate/methacrylic acid copolymer.
Claim 5
Dependent Claim
12 words
A therapeutic composition of claim 1 wherein the therapeutic agent is calcitonin.
Claim 6
Dependent Claim
13 words
A therapeutic composition of claim 1 wherein the therapeutic agent is an antibiotic.
Claim 7
Dependent Claim
25 words
A therapeutic composition of claim 5 wherein the antibiotic is selected from the group consisting of β-lactam antibiotics, tetracycline antibiotics, aminosugar antibiotics and peptide antibiotics.
Claim 8
Dependent Claim
13 words
A therapeutic composition of claim 1 wherein the therapetuic agent is a hormone.
Claim 9
Dependent Claim
12 words
A therapeutic composition of claim 7 wherein the hormone is peptide hormone.
Claim 10
Dependent Claim
108 words
A therapeutic composition for rectal or vaginal administration having excellent absorption properties containing a therapeutically effective amount of a water soluble therapeutic agent having a partition coefficient of up to 50 in chloroform/water and additionally containing: 1. from 0.1 to 50 w/w% of a water soluble chelating agent selected from the group consisting of polysaccharide compounds, cellulose compounds, starch compounds, dextrose compounds polypeptic compounds and synthetic polymers, said agent being capable of chelating calcium or magnesium ions, having a molecular weight of from 1000 to 1,000,000 and containing at least two chelating ligands selected from the group consisting carboxylic, sulfonic, phosphoric, phenolic, hydroxyl, carbonyl, imino and amino groups;
Claim 11
Dependent Claim
108 words
A therapeutic composition for rectal or vaginal administration having excellent absorption properties containing a therapeutically effective amount of a water soluble therapeutic agent having a partition coefficient of up to 50 in chloroform/water and additionally containing: 1. from 0.1 to 50 w/w% of a water soluble chelating agent selected from the group consisting of polysaccharide compounds, cellulose compounds, starch compounds, dextrose compounds polypeptic compounds and synthetic polymers, said agent being capable of chelating calcium or magnesium ions, having a molecular weight of from 1000 to 1,000,000 and containing at least two chelating ligands selected from the group consisting carboxylic, sulfonic, phosphoric, phenolic, hydroxyl, carbonyl, imino and amino groups;
Claim 12
Dependent Claim
63 words
from 0.1 to 50 w/w% of a water soluble solute elected from the group consisting of halides, sulfates, phosphates and carbonates of alkali metals, and mono-and diaccharides, the total concentration of solute being sufficient so that the composition when dissolved in a fixed amount of aqueous media exerts an osmotic pressure 1.5 to 6 times the osmotic pressure of isotonic sodium chloride solution.
Claim 13
Dependent Claim
63 words
from 0.1 to 50 w/w% of a water soluble solute elected from the group consisting of halides, sulfates, phosphates and carbonates of alkali metals, and mono-and diaccharides, the total concentration of solute being sufficient so that the composition when dissolved in a fixed amount of aqueous media exerts an osmotic pressure 1.5 to 6 times the osmotic pressure of isotonic sodium chloride solution.
Claim 14
Dependent Claim
72 words
A therapeutic composition of claim 9 wherein the water soluble chelating agent is selected from the group consisting alginic acid, pectinic acid, chondroitin sulfate, hyaluronic acid, arabic acid; carboxymethyl cellulose, carboxyethyl cellulose, carboxypropyl cellulose, cellulose acetate phthalate; carboxymethyl starch, carboxyethyl starch; carboxymethyl dextran, dextran sulfate; polyglutamic acid, poly-γ-carboxyglutamic acid, polyaspartic acid, polylysine, polyalginine and copolymers of these amino acids; polyacrylic acid, polymethacrylic acid, methacrylic acid-acrylic acid copolymer, acrylamideacrylic acid copolymer, polyphosphoric acid.
Claim 15
Dependent Claim
100 words
A therapeutic composition of claim 9 wherein the water soluble chelating agent is selected from the group consisting chondroitin sulfate, heparin arabic acid, pectin, gum tragacanth, tragacanthic acid, pectinic acid; carrageenan, β-glucan, galactomanna konjakmannan, galactan, fucan, unulin, levan; hydroxyethyl cellulose, hydroxypropyl cellulose, cellulose, methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, agarose; soluble starch, phosphoric acid starch, acetyl starch, hydroxyethyl starch, dextrin, amylose, amylopectin; dextran, diethylaminoethyl dextran, aminoethyl dextran; gelatin, casein, albumin, globulin; polyethylene glycol, polyvinyl alcohol, polyethylene oxide, vinyl acetate-maleic acid copolymer, vinyl acetate-crotonic acid copolymer, vinyl acetate-acrylic acid copolymer, polyvinyl alcohol-maleric acid copolymer, polyacrylamide, polyvinylacetal diethylaminoacetate, 2-methyl-5-vinylpyridine/methyl acrylate/methacrylic acid copolymer.
Claim 16
Dependent Claim
12 words
A therapeutic composition of claim 9 wherein the therapeutic agent is calcitonin.
Claim 17
Dependent Claim
15 words
A therapeutic composition of claim 9 wherein the water soluble therapeutic agent is an antibiotic.
Claim 18
Dependent Claim
25 words
A therapeutic composition of claim 9 wherein the antibiotic is selected from the group consisting of β-lactam antibiotics, tetracycline antibiotics, aminosugar antibiotics and peptide antibiotics.
Claim 19
Dependent Claim
15 words
A therapeutic composition of claim 9 wherein the water soluble therapeutic agent is a hormone.
Claim 20
Dependent Claim
14 words
A therapeutic vagina composition of claim 15 wherein the hormone is a peptide hormone.
References Cited (Backward Citations)
US4166847A
Cited
US4241051A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-09-01 | 1990-03-03 | 1990-09-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-09-01 | 1994-03-03 | 1994-09-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-09-01 | 1998-03-03 | 1998-09-02 | $7700.00 | Window Closed / Lapsed |